Melatonin has clinical utility in the management of cardiac hypertrophy and affords protection in an array of different preclinical models, with effects variously attributed, including to an increase in PGC-1b [78], cyclophilin A/CD147 [79], antioxidant effects [80], retinoic acid receptor-related orphan receptor-α (RORα) [81], autophagy and AMPK [82] or a decrease in mTOR [83] and TNF-α [84]. This evidence concerns the gene MTOR and cardiac hypertrophy.